

THE HEART SHOT

By Craig Paardekooper

Data source : [here](#)

Background : [here](#)

Myocarditis

The incidence of myocarditis with mRNA vaccines such as Comirnaty, Tozinameran, Moderna and Spikevax is much higher than the incidence with adenovirus vector vaccines such as Vaxzevria / Astrazeneca. The risk is 10 x greater with mRNA vaccines.

Reporting Incidence is 0.3% with mRNA, and 0.03% with adenovirus vector vaccines. The Proportional Reporting Ratio for myocarditis with Comirnaty is 3.65 meaning that the incidence is 3.65 times higher than the average for all other drugs.

DRUG	myocarditis	DRUG-TOTAL	%	OTHER-TOT	OTHER-SYM	% OTHER	PRR
TISLELIZUMAB	127	5442	2.3337	14982222	18711	0.12	18.69
IPILIMUMAB	269	16144	1.6663	14971520	18569	0.12	13.43
PEMBROLIZUMAB	258	18920	1.3636	14968744	18580	0.12	10.99
LIBTAYO	25	2192	1.1405	14985472	18813	0.13	9.08
BAVENCIO	25	2240	1.1161	14985424	18813	0.13	8.89
POTELIGEO	14	1464	0.9563	14986200	18824	0.13	7.61
OPDIVO	275	32011	0.8591	14955653	18563	0.12	6.92
KEYTRUDA	868	107405	0.8082	14880259	17970	0.12	6.69
AVELUMAB	16	1911	0.8373	14985753	18822	0.13	6.67
AXITINIB	22	4092	0.5376	14983572	18816	0.13	4.28
NIVOLUMAB	17	3379	0.5031	14984285	18821	0.13	4.01
COMIRNATY	9696	3373553	0.2874	11614111	9142	0.08	3.65
TOZINAMERAN	1761	534703	0.3293	14452961	17077	0.12	2.79
SPIKEVAX	3278	1308687	0.2505	13678977	15560	0.11	2.2
MODERNA	109	48233	0.226	14939431	18729	0.13	1.8
ARIPIRAZOLE	32	16231	0.1972	14971433	18806	0.13	1.57
TAMIFLU	26	15594	0.1667	14972070	18812	0.13	1.33
OLANZAPINE	68	44801	0.1518	14942863	18770	0.13	1.21
YERVOY	14	9754	0.1435	14977910	18824	0.13	1.14
PACLITAXEL	12	9586	0.1252	14978078	18826	0.13	1
PREVENAR	14	12728	0.11	14974936	18824	0.13	0.88
LENVIMA	13	12696	0.1024	14974968	18825	0.13	0.81
NIMENRIX	11	10985	0.1001	14976679	18827	0.13	0.8
AZATHIOPRINE	12	12526	0.0958	14975138	18826	0.13	0.76
TAGRISSO	15	18105	0.0829	14969559	18823	0.13	0.66
CABOMETYX	17	20988	0.081	14966676	18821	0.13	0.64
BEVACIZUMAB	13	17625	0.0738	14970039	18825	0.13	0.59
PANDEMRIX	29	50551	0.0574	14937113	18809	0.13	0.46
INLYTA	14	24400	0.0574	14963264	18824	0.13	0.46
IBUPROFEN	13	24346	0.0534	14963318	18825	0.13	0.42
ENTYVIO	14	28583	0.049	14959081	18824	0.13	0.39
GARDASIL9	19	41282	0.046	14946382	18819	0.13	0.37
STELARA	17	36132	0.047	14951532	18821	0.13	0.37

ABILIFY	11	24065	0.0457	14963599	18827	0.13	0.36
ALIMTA	10	24330	0.0411	14963334	18828	0.13	0.33
CICLOSPORIN	27	70877	0.0381	14916787	18811	0.13	0.3
VAXZEVRIA	289	746718	0.0387	14240946	18549	0.13	0.3
ASTRAZENECA	473	1410636	0.0335	13577028	18365	0.14	0.25
XOLAIR	17	62383	0.0273	14925281	18821	0.13	0.22
GARDASIL	22	95990	0.0229	14891674	18816	0.13	0.18
ZYPREXA	16	69954	0.0229	14917710	18822	0.13	0.18
SHINGRIX	14	61107	0.0229	14926557	18824	0.13	0.18
PEGASYS	11	55966	0.0197	14931698	18827	0.13	0.16
AVANDIA	10	64634	0.0155	14923030	18828	0.13	0.12

Pericarditis

The incidence of pericarditis with mRNA vaccines such as Comirnaty, Tozinameran, Moderna and Spikevax is much higher than the incidence with adenovirus vector vaccines such as Vaxzevria / Astrazeneca. The risk is 10 x greater with mRNA vaccines.

Reporting Incidence is 0.3% with mRNA, and 0.03% with adenovirus vector vaccines.

DRUG	pericarditis	DRUG-TOTAL	%	OTHER-TOT	OTHER-SYM	% OTHER	PRR
ERELZI	11	1777	0.619	14985887	19553	0.13	4.74
COMIRNATY	11241	3373553	0.3332	11614111	8323	0.07	4.65
ARAVA	348	85849	0.4054	14901815	19216	0.13	3.14
MODERNA	173	48233	0.3587	14939431	19391	0.13	2.76
ADALIMUMAB	127	35443	0.3583	14952221	19437	0.13	2.76
TOZINAMERAN	1772	534703	0.3314	14452961	17792	0.12	2.69
NILOTINIB	16	4783	0.3345	14982881	19548	0.13	2.56
SPIKEVAX	3110	1308687	0.2376	13678977	16454	0.12	1.98
ILARIS	11	4696	0.2342	14982968	19553	0.13	1.79
ABATACEPT	21	11727	0.1791	14975937	19543	0.13	1.37
BENLYSTA	51	28458	0.1792	14959206	19513	0.13	1.37
SPRYCEL	46	26888	0.1711	14960776	19518	0.13	1.31
BOSULIF	17	10275	0.1655	14977389	19547	0.13	1.27
ZELBORAF	14	8859	0.158	14978805	19550	0.13	1.21
PEMBROLIZUMAB	29	18920	0.1533	14968744	19535	0.13	1.17
REMICADE	11	7440	0.1478	14980224	19553	0.13	1.13
KYPROLIS	12	8300	0.1446	14979364	19552	0.13	1.11
APIXABAN	17	11914	0.1427	14975750	19547	0.13	1.09
RITUXIMAB	40	28864	0.1386	14958800	19524	0.13	1.06
STELARA	39	36132	0.1079	14951532	19525	0.13	0.83
ENTYVIO	29	28583	0.1015	14959081	19535	0.13	0.78
IBUPROFEN	24	24346	0.0986	14963318	19540	0.13	0.75
TASIGNA	32	32960	0.0971	14954704	19532	0.13	0.74
KEYTRUDA	100	107405	0.0931	14880259	19464	0.13	0.71
IPILIMUMAB	14	16144	0.0867	14971520	19550	0.13	0.66
AZATHIOPRINE	10	12526	0.0798	14975138	19554	0.13	0.61
HUMIRA	21	27735	0.0757	14959929	19543	0.13	0.58
PEGASYS	42	55966	0.075	14931698	19522	0.13	0.57
AVANDAMET	10	13999	0.0714	14973665	19554	0.13	0.55
OPDIVO	22	32011	0.0687	14955653	19542	0.13	0.53
CIMZIA	45	68318	0.0659	14919346	19519	0.13	0.5

ALIMTA	14	24330	0.0575	14963334	19550	0.13	0.44
ENBREL	22	38127	0.0577	14949537	19542	0.13	0.44
METHOTREXATE	21	36504	0.0575	14951160	19543	0.13	0.44
COSENTYX	32	58446	0.0548	14929218	19532	0.13	0.42
AVANDIA	35	64634	0.0542	14923030	19529	0.13	0.41
SHINGRIX	32	61107	0.0524	14926557	19532	0.13	0.4
CYTARABINE	11	22455	0.049	14965209	19553	0.13	0.37
SIMPONI	17	35273	0.0482	14952391	19547	0.13	0.37
XOLAIR	30	62383	0.0481	14925281	19534	0.13	0.37
PANDEMRIX	24	50551	0.0475	14937113	19540	0.13	0.36
CELLCEPT	15	33037	0.0454	14954627	19549	0.13	0.35
VAXZEVRIA	301	746718	0.0403	14240946	19263	0.14	0.3
XELJANZ	41	109396	0.0375	14878268	19523	0.13	0.29
GARDASIL9	15	41282	0.0363	14946382	19549	0.13	0.28
ASTRAZENECA	449	1410636	0.0318	13577028	19115	0.14	0.23
SOLIRIS	12	41998	0.0286	14945666	19552	0.13	0.22
CICLOSPORIN	17	70877	0.024	14916787	19547	0.13	0.18
GARDASIL	16	95990	0.0167	14891674	19548	0.13	0.13
ELIQUIS	23	141266	0.0163	14846398	19541	0.13	0.12
ZOSTAVAX	12	73453	0.0163	14914211	19552	0.13	0.12
SUTENT	14	96971	0.0144	14890693	19550	0.13	0.11

Myopericarditis

DRUG	myopericarditis	DRUG-TOTAL	%	OTHER-TOT	OTHER-SYM	% OTHER	PRR
MODERNA	54	48233	0.112	14939431	3186	0.02	5.25
TOZINAMERAN	427	534703	0.0799	14452961	2813	0.02	4.1
SPIKEVAX	850	1308687	0.065	13678977	2390	0.02	3.72
COMIRNATY	1669	3373553	0.0495	11614111	1571	0.01	3.66
KEYTRUDA	14	107405	0.013	14880259	3226	0.02	0.6
VAXZEVRIA	43	746718	0.0058	14240946	3197	0.02	0.26
ASTRAZENECA	42	1410636	0.003	13577028	3198	0.02	0.13

For some reason, mRNA Covid shots were attacking the heart BUT adenovirus Covid shots were not.

Why are mRNA vaccines more toxic for heart muscle ?

Differences between mRNA and Viral-vector Vaccines

<https://www.youtube.com/watch?v=0Zhwc8jQIVM>

The Genetic Content of the Delivery Vehicle

mRNA vaccines and virus-vector vaccines both deliver a genetic cargo that is supposed to produce the spike protein only. This has now become a controversial issue with the discovery of undisclosed sequences within the mRNA – including undisclosed amyloidogenic sequences, sequences for SV40, sequences for anti-biotic resistance, plasmid DNA sequences, and fragmentary sequences of mRNA that have unknown effects. See <https://howbad.info/prion4.pdf>

This high variability in the mRNA content, compared to the DNA in viral-vector vaccines may be a factor in explaining the higher cardio-toxicity of the mRNA Covid jabs.

The Delivery Vehicle

mRNA uses lipid-nano-particles as the delivery mechanism which are able to merge and pass into any cell. In comparison, virus-vector vaccines use a virus shell as the delivery vehicle.

A viral-vector will be recognized by the immune system and therefore will elicit more immune resistance. In contrast LNPs lack any viral features on their surface, so will escape immune surveillance.

It is therefore likely that mRNA vaccines will have a greater biodistribution, and will be able to deliver their cargo into more cell types.

The Expression Kinetics and Immunogenicity of Lipid Nanoparticles Delivering Plasmid DNA and mRNA in Mice (2023) by Zhang et al <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610642/>

First, encapsulation in an LNP protects nucleic acids from degradation and improves stability in biological fluids [2,3,4,5]. Second, LNPs improve cellular uptake, leading to increased expression of the target antigen, which may contribute to increased immunogenicity [5,6,7,8,9]. Third, nucleic acid vaccines delivered by LNPs do not require additional adjuvants for immune activation [10,11]. Finally, when compared to delivery by viral vectors, LNP-based vaccines are more easily produced and do not induce anti-vector immunity that may hinder vaccine efficacy [12].

“LNPs improve cellular uptake, leading to increased expression of the target antigen”, but this could be a disadvantage if cardiac muscle cells uptake these LNPs, express the antigen, and are then attacked by the immune system.

“LNP-based vaccines...do not induce anti-vector immunity.” If LNPs escape immune surveillance before merging with cells, then the LNPs will persist for longer and bio-distribution will be greater. LNP will get into more cells resulting in a more intense immune reaction.

Lipid Nano-particles for Gene Delivery (2014) by Zhao et al <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006671/>

“LNPs are safer than viral vectors due to the absence of immunogenic viral proteins.” Meaning that the viral shell normally elicits immune resistance which PROTECTS your body from the viral cargo. LNPs avoid this resistance because their surface contains no viral proteins. Therefore LNPs expose your body in an unnatural

way to a more intense load of the viral cargo. The use of the word “safer” in this quote only applies if the cargo is a self-antigen – such as if used to restore a natural sequence that had become mutated.

If the cargo of the LNPs were a **self-antigen** – in other words one that WILL NOT elicit an immune response – then LNPs might be used for therapeutic ends. But if the cargo of the LNPs is a **foreign antigen**, then there will be immune attack upon the cells expressing that antigen. If cells attacked happen to be nerve or heart cells, then cell death and fibrosis will result. If the immune system learns to identify the cell with the antigen, then an **autoimmune disease** may also result.

Consequently, it is logical to conclude that – **LNPs have a place in therapeutic use where the cargo is a SELF-ANTIGEN, but not in immunogenic uses where the cargo is a FOREIGN ANTIGEN.**

Immunogenic use should therefore be regarded as a way of inducing harm – a form of weaponry – more suited to military goals rather than health goals.

Acknowledgement

These conclusions are only possible because of the sacrifice of 14,844 people who developed myocarditis, 16,296 people who developed pericarditis, and 3000 people who developed myopericarditis after taking an mRNA vaccine against Covid, as recorded in the European Medical Association pharma-vigilance system.

“The Science” has now evolved in its understanding of the dangers of mRNA vaccines – including

1. Expression of a **foreign antigen** in vital organs remote from the injection site, will result in autoimmune attack and organ failure.
2. Use of a **toxic antigen** instead of a non-toxic one (the spike protein is inherently toxic) will result in toxic effects. See [here](#), and [here](#)
3. Inclusion of undisclosed sequences within the genetic cargo will generate **undisclosed antigens** such as SV40, amyloid formation and antibiotic resistance, and these will result in additional toxic effects. See [here](#)

Note : A possible reason why Vaxzevria and Astrazeneca are associated with significantly higher incidence of thrombosis is because these vaccines may generate a high amount of free floating spike protein in the circulatory system. Spike protein is known to be a powerful blood coagulant, and therefore clotting would result.